At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 383 enrolled
Drug / intervention
Tadalafil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Evaluation of Tadalafil and Sildenafil Treatment in Men With Erectile Dysfunction in China
In Brief
A Phase 4 clinical trial evaluating Tadalafil and Sildenafil for Erectile Dysfunction. Completed, enrolled 383 participants across 9 sites.
Detailed Summary
The primary objective of this study is to evaluate whether, after two 8-week treatment periods, male patients with erectile dysfunction (ED) in China prefer 20 milligram (mg) tadalafil or 100 mg sildenafil. This trial consists of two treatment periods of 8 weeks each and an extension phase of 8 weeks, for a total of 24 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionJun 2012
Study CompletionJul 2012
TodayJul 2026
First PostedMay 12, 2011
Enrollment StartJun 1, 2011
Primary CompletionJun 1, 2012
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.1 years ago
Interventions
Tadalafildrug
Administered Orally
Sildenafildrug
Administered Orally